Last reviewed · How we verify
Albumin infusion
Albumin infusion restores circulating plasma volume and oncotic pressure by providing exogenous human serum albumin, a major blood protein.
Albumin infusion restores circulating plasma volume and oncotic pressure by providing exogenous human serum albumin, a major blood protein. Used for Hypovolemia and shock management, Severe burns, Liver cirrhosis with ascites.
At a glance
| Generic name | Albumin infusion |
|---|---|
| Also known as | Albumin, Albutein |
| Sponsor | University Hospital Hradec Kralove |
| Drug class | Blood product / Plasma protein fraction |
| Modality | Small molecule |
| Therapeutic area | Critical Care / Hematology |
| Phase | Phase 3 |
Mechanism of action
Albumin is the most abundant plasma protein and serves critical functions in maintaining colloid osmotic pressure, which regulates fluid distribution between intravascular and interstitial compartments. Infusion of albumin increases plasma oncotic pressure, drawing fluid into the vasculature and expanding circulating volume. This is used therapeutically in conditions involving hypovolemia, hypoalbuminemia, or fluid shifts such as severe burns, liver disease, or sepsis.
Approved indications
- Hypovolemia and shock management
- Severe burns
- Liver cirrhosis with ascites
- Hypoalbuminemia in critical illness
Common side effects
- Hypervolemia / fluid overload
- Allergic reaction
- Fever
- Chills
- Nausea
Key clinical trials
- A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) (PHASE3)
- Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023] (PHASE3)
- Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma (PHASE2)
- A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors (PHASE1, PHASE2)
- A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) (PHASE3)
- Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss (PHASE3)
- A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016) (PHASE3)
- Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Albumin infusion CI brief — competitive landscape report
- Albumin infusion updates RSS · CI watch RSS
- University Hospital Hradec Kralove portfolio CI